KBL Merger Corp. IV

  • Investors
  • Overview
  • Team
  • Press Releases
  • SEC Filings
  • 180 Life Sciences
  • Email Alerts
  • Contact

Press Releases

Oct 05, 2020 8:30am EDT

Development of Next-Generation Drugs to Inhibit Ravages of Chronic Inflammation

Oct 01, 2020 8:30am EDT

Groundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory Disease

Jun 29, 2020 7:30am EDT

KBL Merger Corp. IV SPAC Successfully Completes Bridge Financing

Jul 26, 2019 9:00am EDT

KBL Merger Corp. IV SPAC Signs Definitive Business Combination Agreement to Acquire CannBioRx Life Sciences Corp.

May 14, 2019 8:00am EDT

KBL Merger Corp. IV SPAC Announces Non-Binding Term Sheet to Acquire CannBioRx Life Sciences Corp. and its Three Interactive Programs

Jun 23, 2017 4:32pm EDT

KBL Merger Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Full in Connection with its Initial Public Offering and Separate Trading of its Common Stock, Rights and Warrants, Commencing June 27, 2017

Jun 07, 2017 4:01pm EDT

KBL Merger Corp. IV Completes $100 Million Initial Public Offering

Jun 01, 2017 8:21pm EDT

KBL Merger Corp. IV Announces Pricing of $100 Million Initial Public Offering

  • Previous
  • 1
  • 2
RSS
  • Email Alerts
  • RSS News Feed
© 2021 KBL Merger Corp. IV. All Rights Reserved.
Sitemap